The combination of anti-4BB anti-agonist antibodies, anti-CTLA-4 antibodies, and targeted irradiation has led to a 50 percent increase in tumor-infiltrating lymphocytes and a 50 percent increase in tumor-free survival [226]. Here, CTLA4 is linked to neoplasm.